利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

93 条记录 (耗时 0.037 秒)

    Method of Proliferating Plasma Cells
    32.
    发明申请
    Method of Proliferating Plasma Cells 失效
    增殖血浆细胞的方法

    公开(公告)号：US20120015402A1

    公开(公告)日：2012-01-19

    申请号：US13187677

    申请日：2011-07-21

    申请人： Masayuki Tsuchiya ,  Masami Suzuki ,  Kenji Yoshida ,  Etsuko Fujii ,  Miho Watanabe ,  Koichi Matsubara ,  Yu Jau Chen ,  Juliana Sim

    发明人： Masayuki Tsuchiya ,  Masami Suzuki ,  Kenji Yoshida ,  Etsuko Fujii ,  Miho Watanabe ,  Koichi Matsubara ,  Yu Jau Chen ,  Juliana Sim

    IPC分类号： C12P21/00 ,  C12N5/071

    CPC分类号： A01K67/027 ,  A01K2267/01 ,  A61K35/16 ,  C07K16/00 ,  C07K16/30

    摘要： An objective of the present invention is to facilitate the acquisition of antibody-producing cells that are infiltrating virus-infected cells, cancer cells, abnormal cells forming a benign hyperplasia, and the like, and to improve the efficiency of the production of antibodies as well as nucleic acids encoding them from the antibody-producing cells.The present inventors discovered that, when cancer tissues comprising infiltrating lymphocytes are transplanted into highly immunodeficient animals that do not have T cells, B cells, and NK cells and further exhibit a low IFN production ability, the differentiation and proliferation of infiltrating lymphocytes are unexpectedly promoted, and the number of plasma cells that produce antibodies recognizing cancer tissues increases dramatically, plasma cells can be separated easily, and antibodies or nucleic acids encoding them can be easily prepared from the plasma cells.

    摘要翻译： 本发明的目的是便于获得渗透病毒感染细胞的抗体产生细胞，癌细胞，形成良性增生的异常细胞等，以及提高抗体生产的效率 作为从抗体产生细胞编码它们的核酸。 本发明人发现，当将包含浸润性淋巴细胞的癌组织移植到不具有T细胞，B细胞和NK细胞的高度免疫缺陷的动物中并且进一步表现出低的IFN产生能力时，意外地促进了浸润性淋巴细胞的分化和增殖 并且产生识别癌组织的抗体的浆细胞的数量急剧增加，可以容易地分离浆细胞，并且可以容易地从浆细胞制备抗体或编码它们的核酸。

    Reshaped human antibody to human medulloblastoma cells
    35.
    发明授权
    Reshaped human antibody to human medulloblastoma cells 失效
    人成神经管细胞瘤细胞的人源化抗体

    公开(公告)号：US07563599B2

    公开(公告)日：2009-07-21

    申请号：US10839799

    申请日：2004-05-06

    申请人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    发明人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    IPC分类号： C12P21/04 ,  C07H21/04 ,  C12P21/08 ,  C07K16/00

    CPC分类号： C07K16/3053 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00

    摘要： The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.

    摘要翻译： 本发明公开了对人成神经管细胞瘤细胞重整的抗体，其包含：（A）L链，其包含：（1）人L链C区，和（2）包含人L链FR和L链CDR的L链V区 单克隆抗体ONS-M21给人成神经管细胞瘤细胞; 和（B）包含以下物质的H链：（1）人H链C区，和（2）包含人H链FR的H链V区和小鼠单克隆抗体ONS-M21的H链CDR至人成神经管细胞瘤细胞。 由于这种重构的人抗体的大部分来自人抗体，小鼠CDR具有低水平的抗原性，所以本发明的重构人（人源化）抗体在人中具有低水平的抗原性，因此预期为 可用作用于脑肿瘤如成神经管细胞瘤的治疗剂和诊断工具，其能强烈表达被该抗体识别的抗原。

    Cell Death-Inducing Agents
    37.
    发明申请
    Cell Death-Inducing Agents 审中-公开
    细胞死亡诱导剂

    公开(公告)号：US20080274110A1

    公开(公告)日：2008-11-06

    申请号：US11547747

    申请日：2004-04-09

    申请人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    发明人： Shuji Ozaki ,  Masahiro Abe ,  Masayuki Tsuchiya ,  Naoki Kimura ,  Shigeto Kawai

    IPC分类号： A61K39/395 ,  C07K16/00 ,  A61P35/04 ,  C12N5/02

    CPC分类号： C07K16/2833 ,  C07K2317/34 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/626 ,  C07K2317/73

    摘要： To identify antigens of the 2D7 antibody, the present inventors cloned the 2D7 antigen. As a result, the 2D7 antibody was found to recognize HLA class IA. In addition, the present inventors examined whether the 2D7 antibody has cell death-inducing activity. Nuclei fragmentation was observed when the 2D7 antibody was cross-linked with another antibody, indicating that cell-death was induced. Further, diabodies of the 2D7 antibody were found to have very strong cell death-inducing activities, even without the addition of another antibody. These results indicate that minibodies of an HLA-recognizing antibody can be used as cell death-inducing agents.

    摘要翻译： 为了鉴定2D7抗体的抗原，本发明人克隆了2D7抗原。 结果发现2D7抗体识别HLA类别IA。 此外，本发明人检查了2D7抗体是否具有细胞死亡诱导活性。 当2D7抗体与另一种抗体交联时，观察到细胞核碎裂，表明诱导细胞死亡。 此外，发现2D7抗体的双抗体具有非常强的细胞死亡诱导活性，即使没有添加另一种抗体。 这些结果表明HLA识别抗体的小体抗体可以用作细胞死亡诱导剂。

    Ligand having agonistic activity to mutated receptor
    39.
    发明申请
    Ligand having agonistic activity to mutated receptor 失效
    配体对突变受体具有激动作用

    公开(公告)号：US20060189794A1

    公开(公告)日：2006-08-24

    申请号：US10548727

    申请日：2004-03-12

    申请人： Masayuki Tsuchiya ,  Yuichi Hirata

    发明人： Masayuki Tsuchiya ,  Yuichi Hirata

    IPC分类号： A61K39/395 ,  C07K16/28

    CPC分类号： C09K11/7733 ,  G21K4/00

    摘要： The present inventors used antibody engineering techniques to prepare functional antibodies that correspond to individual mutations in causative genes of diseases, and discovered that such antibodies enable the treatment of the diseases. Specifically, the inventors succeeded in preparing ligands, particularly minibodies, which have agonistic activity to receptors that have almost completely lost responsiveness to their natural ligands because of gene mutations (for example, a thrombopoietin (TPO) receptor whose reactivity to TPO has been markedly impaired), and which can transduce signals by interacting with these mutant receptors at levels comparable to normal.

    摘要翻译： 本发明人使用抗体工程技术来制备与疾病的致病基因中的个体突变相对应的功能性抗体，并发现这种抗体能够治疗疾病。 具体地，本发明人成功地制备了由于基因突变（例如，其对TPO的反应性已被显着损伤的血小板生成素（TPO）受体）而对几乎完全丧失对其天然配体的反应性的受体具有激动作用的配体，特别是微型抗体 ），并且其可以通过与这些突变体受体的相互作用来转导信号，其水平与正常水平相当。

    Reshaped human antibody to human medulloblastoma cells
    40.
    发明申请
    Reshaped human antibody to human medulloblastoma cells 失效
    人成神经管细胞瘤细胞的人源化抗体

    公开(公告)号：US20050249726A1

    公开(公告)日：2005-11-10

    申请号：US10839799

    申请日：2004-05-06

    申请人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    发明人： Toshihiko Ohtomo ,  Koh Sato ,  Masayuki Tsuchiya

    IPC分类号： A61K38/00 ,  A61K39/395 ,  C07H21/04 ,  C07K16/30 ,  C07K16/44 ,  C12N5/06 ,  C12P21/06 ,  C12P21/08

    CPC分类号： C07K16/3053 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/00

    摘要： The present invention discloses reshaped antibody to human medulloblastoma cells comprising: (A) an L chain comprising: (1) a human L chain C region, and (2) an L chain V region comprising human L chain FRs and L chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells; and, (B) an H chain containing: (1) a human H chain C region, and (2) an H chain V region comprising human H chain FRs and H chain CDRs of mouse monoclonal antibody ONS-M21 to human medulloblastoma cells. Since the majority of this reshaped human antibody is derived from a human antibody and mouse CDRs have a low level of antigenicity, the reshaped human antibody of the present invention has a low level of antigenicity in humans, and is therefore expected to be useful as a therapeutic agent and diagnostic tool for brain tumors such as medulloblastoma which strongly express antigen that is recognized by this antibody.

    摘要翻译： 本发明公开了对人成神经管细胞瘤细胞重整的抗体，其包含：（A）L链，其包含：（1）人L链C区，和（2）包含人L链FR和L链CDR的L链V区 单克隆抗体ONS-M21给人成神经管细胞瘤细胞; 和（B）包含以下物质的H链：（1）人H链C区，和（2）包含人H链FR的H链V区和小鼠单克隆抗体ONS-M21的H链CDR至人成神经管细胞瘤细胞。 由于这种重构的人抗体的大部分来自人抗体，小鼠CDR具有低水平的抗原性，所以本发明的重构人（人源化）抗体在人中具有低水平的抗原性，因此预期为 可用作用于脑肿瘤如成神经管细胞瘤的治疗剂和诊断工具，其能强烈表达被该抗体识别的抗原。